Equities Analysts Set Expectations for CorMedix Q1 Earnings

CorMedix Inc. (NASDAQ:CRMD - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for CorMedix in a report issued on Tuesday, March 25th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of $0.23 per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix's Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.73 EPS, FY2026 earnings at $2.50 EPS, FY2027 earnings at $3.20 EPS and FY2028 earnings at $3.65 EPS.

CorMedix (NASDAQ:CRMD - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.05. The firm had revenue of $30.00 million during the quarter, compared to analysts' expectations of $27.46 million. The company's quarterly revenue was up 29900.0% compared to the same quarter last year.

Several other research firms have also commented on CRMD. Needham & Company LLC lowered their price objective on shares of CorMedix from $18.00 to $12.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Royal Bank of Canada reissued an "outperform" rating and set a $12.00 price objective on shares of CorMedix in a research note on Wednesday, March 26th. Leerink Partners began coverage on CorMedix in a research note on Friday, March 7th. They issued an "outperform" rating and a $18.00 price objective for the company. Finally, D. Boral Capital reissued a "buy" rating and set a $15.00 target price on shares of CorMedix in a research report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $15.14.

Remove Ads

CorMedix Price Performance

Shares of NASDAQ CRMD traded down $0.58 during midday trading on Friday, reaching $6.16. 2,345,394 shares of the stock traded hands, compared to its average volume of 991,958. The company's 50 day moving average is $10.43 and its 200 day moving average is $9.93. CorMedix has a one year low of $3.61 and a one year high of $13.85. The stock has a market capitalization of $401.52 million, a PE ratio of -7.60 and a beta of 1.53.

Institutional Trading of CorMedix

Several institutional investors and hedge funds have recently modified their holdings of CRMD. Elliott Investment Management L.P. grew its stake in CorMedix by 85.1% in the fourth quarter. Elliott Investment Management L.P. now owns 2,870,632 shares of the company's stock worth $23,252,000 after purchasing an additional 1,320,109 shares in the last quarter. Palisades Investment Partners LLC bought a new position in shares of CorMedix during the 4th quarter worth $2,949,000. J. Goldman & Co LP increased its stake in shares of CorMedix by 221.1% during the fourth quarter. J. Goldman & Co LP now owns 457,320 shares of the company's stock valued at $3,704,000 after buying an additional 314,880 shares during the period. Vanguard Group Inc. raised its holdings in shares of CorMedix by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 3,378,191 shares of the company's stock valued at $27,363,000 after acquiring an additional 309,514 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in CorMedix by 685.5% in the third quarter. JPMorgan Chase & Co. now owns 194,108 shares of the company's stock worth $1,568,000 after acquiring an additional 169,397 shares during the period. Institutional investors own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.